Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
2373
mi
from 98109
Philadelphia, PA
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
CCOP - Upstate Carolina
2242
mi
from 98109
Spartanburg, SC
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
CCOP - Upstate Carolina
2242
mi
from 98109
Spartanburg, SC
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
Rapid City Regional Hospital
949
mi
from 98109
Rapid City, SD
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
Rapid City Regional Hospital
949
mi
from 98109
Rapid City, SD
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
705
mi
from 98109
Murray, UT
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
705
mi
from 98109
Murray, UT
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
Dixie Regional Medical Center - East Campus
851
mi
from 98109
Saint George, UT
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
Dixie Regional Medical Center - East Campus
851
mi
from 98109
Saint George, UT
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
University Cancer Center at University of Washington Medical Center
28
mi
from 98109
Seattle, WA
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
University Cancer Center at University of Washington Medical Center
28
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
1646
mi
from 98109
Green Bay, WI
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
1646
mi
from 98109
Green Bay, WI
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
St. Vincent Hospital Regional Cancer Center
1646
mi
from 98109
Green Bay, WI
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
St. Vincent Hospital Regional Cancer Center
1646
mi
from 98109
Green Bay, WI
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
Gundersen Lutheran Center for Cancer and Blood
1512
mi
from 98109
La Crosse, WI
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
Gundersen Lutheran Center for Cancer and Blood
1512
mi
from 98109
La Crosse, WI
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
1615
mi
from 98109
Madison, WI
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
1615
mi
from 98109
Madison, WI
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
Bay Area Cancer Care Center at Bay Area Medical Center
1649
mi
from 98109
Marinette, WI
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
Bay Area Cancer Care Center at Bay Area Medical Center
1649
mi
from 98109
Marinette, WI
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
Medical College of Wisconsin Cancer Center
1681
mi
from 98109
Milwaukee, WI
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
Medical College of Wisconsin Cancer Center
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
Hopital Notre-Dame du CHUM
2282
mi
from 98109
Montreal,
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
Hopital Notre-Dame du CHUM
2282
mi
from 98109
Montreal,
Click here to add this to my saved trials
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated:  11/6/2017
Baptist Medical Center South
2466
mi
from 98109
Jacksonville, FL
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Status: Enrolling
Updated: 11/6/2017
Baptist Medical Center South
2466
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  11/7/2017
City of Hope
959
mi
from 98109
Duarte, CA
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 11/7/2017
City of Hope
959
mi
from 98109
Duarte, CA
Click here to add this to my saved trials
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
Status: Enrolling
Updated:  11/7/2017
City of Hope
959
mi
from 98109
Duarte, CA
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
Status: Enrolling
Updated: 11/7/2017
City of Hope
959
mi
from 98109
Duarte, CA
Click here to add this to my saved trials
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  11/9/2017
University of California at Los Angeles
979
mi
from 98109
Los Angeles, CA
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 11/9/2017
University of California at Los Angeles
979
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy)
Status: Enrolling
Updated:  11/11/2017
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
2024
mi
from 98109
Cleveland, OH
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy)
Status: Enrolling
Updated: 11/11/2017
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Billings Clinic
668
mi
from 98109
Billings, MT
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Billings Clinic
668
mi
from 98109
Billings, MT
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Mayo Clinic Cancer Clinical Studies Unit
1446
mi
from 98109
Rochester, MN
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Mayo Clinic Cancer Clinical Studies Unit
1446
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Hackensack University Medical Center
2394
mi
from 98109
Hackensack, NJ
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Hackensack University Medical Center
2394
mi
from 98109
Hackensack, NJ
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
NYU Cancer Institute - Bellevue Hospital
2402
mi
from 98109
New York, NY
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
NYU Cancer Institute - Bellevue Hospital
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Sarah Cannon Research Institute Drug Development Unit
1970
mi
from 98109
Nashville, TN
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Sarah Cannon Research Institute Drug Development Unit
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Mary Crowley Medical Research Center
1680
mi
from 98109
Dallas, TX
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Mary Crowley Medical Research Center
1680
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Institut Claudius Regaud
2246
mi
from 98109
Toulouse Cedex,
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Institut Claudius Regaud
2246
mi
from 98109
Toulouse Cedex,
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
Cedars-Sinai Medical Center
962
mi
from 98109
Los Angeles, CA
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
Cedars-Sinai Medical Center
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
UCLA Neuro-Oncology Program
962
mi
from 98109
Los Angeles, CA
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
UCLA Neuro-Oncology Program
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated:  11/13/2017
University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center
680
mi
from 98109
San Francisco, CA
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status: Enrolling
Updated: 11/13/2017
University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Status: Enrolling
Updated:  11/15/2017
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Status: Enrolling
Updated: 11/15/2017
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Status: Enrolling
Updated:  11/15/2017
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Status: Enrolling
Updated: 11/15/2017
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  11/15/2017
Washington University School of Medicine
1718
mi
from 98109
Saint Louis, MO
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 11/15/2017
Washington University School of Medicine
1718
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma
A Pilot Study of the Utility of 18F-FLT-PET and Diffusion-Weighted MRI for Surgical Planning, Radiotherapy Target Delineation, and Treatment Response Evaluation in Ewing Sarcoma Patients
Status: Enrolling
Updated:  11/16/2017
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma
A Pilot Study of the Utility of 18F-FLT-PET and Diffusion-Weighted MRI for Surgical Planning, Radiotherapy Target Delineation, and Treatment Response Evaluation in Ewing Sarcoma Patients
Status: Enrolling
Updated: 11/16/2017
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
GA-69 DOTA-TATE Imaging of Somatostatin R+ Malignancies
Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Status: Enrolling
Updated:  11/16/2017
UCSF Imaging Center at China Basin
680
mi
from 98109
San Francisco, CA
GA-69 DOTA-TATE Imaging of Somatostatin R+ Malignancies
Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Status: Enrolling
Updated: 11/16/2017
UCSF Imaging Center at China Basin
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
GA-69 DOTA-TATE Imaging of Somatostatin R+ Malignancies
Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Status: Enrolling
Updated:  11/16/2017
UCSF Medical Center at Mount Zion
680
mi
from 98109
San Francisco, CA
GA-69 DOTA-TATE Imaging of Somatostatin R+ Malignancies
Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Status: Enrolling
Updated: 11/16/2017
UCSF Medical Center at Mount Zion
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
GA-69 DOTA-TATE Imaging of Somatostatin R+ Malignancies
Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Status: Enrolling
Updated:  11/16/2017
UCSF Medical Center-Mission Bay
681
mi
from 98109
San Francisco, CA
GA-69 DOTA-TATE Imaging of Somatostatin R+ Malignancies
Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Status: Enrolling
Updated: 11/16/2017
UCSF Medical Center-Mission Bay
681
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
1616
mi
from 98109
Madison, WI
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
1616
mi
from 98109
Madison, WI
Click here to add this to my saved trials
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
1500
mi
from 98109
Kansas City, KA
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
1500
mi
from 98109
Kansas City, KA
Click here to add this to my saved trials
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated:  11/17/2017
2066
mi
from 98109
Toronto,
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Status: Enrolling
Updated: 11/17/2017
2066
mi
from 98109
Toronto,
Click here to add this to my saved trials
Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS
Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS
Status: Enrolling
Updated:  11/22/2017
Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS
Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS
Status: Enrolling
Updated: 11/22/2017
Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
1393
mi
from 98109
Minneapolis, MN
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  11/28/2017
Ohio State University
2006
mi
from 98109
Columbus, OH
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 11/28/2017
Ohio State University
2006
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
Phase I Study of Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Recurrent or Progressive Malignant Gliomas
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
1393
mi
from 98109
Minneapolis, MN
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
Phase I Study of Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Recurrent or Progressive Malignant Gliomas
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
UAB Comprehensive Cancer Center
2080
mi
from 98109
Birmingham, AL
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
UAB Comprehensive Cancer Center
2080
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/30/2017
Jonsson Comprehensive Cancer Center at UCLA
959
mi
from 98109
Los Angeles, CA
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/30/2017
Jonsson Comprehensive Cancer Center at UCLA
959
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials